About the Episode:

How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations.

Key Takeaways:

How switching to a SC delivery model impacts patients, healthcare providers and drug development companies
Keys to successful partnerships and collaborations
How Halozyme's ENHANZE® technology enables the shift from IV to SC

About the Speaker:

Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme. Ms Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did postgraduate research at MIT/Harvard.

For more information:

About drug delivery and partnerships, click here.

For more information about PharmaTalk Radio, visit theconferenceforum.org.

Making the Leap from IV to Subcutaneous, with Halozyme's ENHANZE® Technology

Share

Embed